Unilever hinted today that it would pursue a deal on GlaxoSmithKline consumer health activities, even commenting that it was in line with its strategy, after rejecting the 50 50 billion ($ 68.4 billion) offer.
GSK confirmed at the weekend that it had rejected the offer of the Dove soap company for consumer health activities, which also hosts brands such as Sensodyne toothpaste.
GSK share is up 5%.
“The acquisition will create a scale and a growth platform for the combined portfolio in the US, China and India, with further opportunities in other emerging markets,” said Unilever, noting the synergies in the oral hygiene and vitamin supplements industry.
GSK said on Saturday that Unilever’s proposal “fundamentally devalues” these activities, adding that it will stick to its plan to list these activities on the stock exchange this year.
GSK’s consumer business, which owns 32% of Pfizer, had annual sales of almost 10 10 billion.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
